KC Creation

KC Creation is a Japanese biotechnology company specializing in regenerative medicine and cell therapy. The company focuses on the development and commercialization of autologous cell-based products, utilizing advanced cell culture technologies. Its lead product, KCC-01 (autologous cultured dermal fibroblasts), received regulatory approval in Japan for the treatment of nasolabial folds. Additionally, the company is advancing KCC-05, an autologous cultured chondrocyte therapy, for the treatment of knee osteoarthritis. KC Creation aims to provide innovative solutions for aging-related conditions and tissue repair through its proprietary cell processing platforms. The company operates its own cell processing centers to ensure high-quality production of its therapeutic candidates.